User contributions for Edzelco
Jump to navigation
Jump to search
20 April 2024
- 03:2103:21, 20 April 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated current
- 03:2003:20, 20 April 2024 diff hist +38,269 Cipaglucosidase alfa-atga No edit summary current
18 April 2024
- 12:4812:48, 18 April 2024 diff hist +96 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 12:4512:45, 18 April 2024 diff hist −220 Momelotinib No edit summary current
- 12:4412:44, 18 April 2024 diff hist +34,290 Momelotinib No edit summary
- 12:1212:12, 18 April 2024 diff hist +26,053 Motixafortide No edit summary current
- 11:4911:49, 18 April 2024 diff hist +2,390 Pozelimab-bbfg No edit summary current
- 11:4211:42, 18 April 2024 diff hist +39,181 Palovarotene No edit summary current
- 11:1611:16, 18 April 2024 diff hist +32,847 Elranatamab-bcmm No edit summary current
17 April 2024
- 08:0808:08, 17 April 2024 diff hist +53 N Elranatamab-bcmm Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0808:08, 17 April 2024 diff hist +53 N Palovarotene Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0808:08, 17 April 2024 diff hist +53 N Pozelimab-bbfg Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0708:07, 17 April 2024 diff hist +53 N Motixafortide Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0708:07, 17 April 2024 diff hist +53 N Momelotinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0608:06, 17 April 2024 diff hist +53 N Cipaglucosidase alfa-atga Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0508:05, 17 April 2024 diff hist +53 N Etrasimod Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0508:05, 17 April 2024 diff hist +53 N Zilucoplan Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Bimekizumab Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Vamorolone Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Mirikizumab-mrkz Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0308:03, 17 April 2024 diff hist +53 N Toripalimab-tpzi Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0208:02, 17 April 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 08:0208:02, 17 April 2024 diff hist +25,648 N Fruquintinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F..." current
- 07:5307:53, 17 April 2024 diff hist +26 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:5307:53, 17 April 2024 diff hist 0 Taurolidine, heparin No edit summary current
- 07:5207:52, 17 April 2024 diff hist +9,993 N Taurolidine, heparin Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients..."
- 07:4407:44, 17 April 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4407:44, 17 April 2024 diff hist +36 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4307:43, 17 April 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4307:43, 17 April 2024 diff hist +32,783 N Repotrectinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru..." current
- 07:3407:34, 17 April 2024 diff hist 0 Efbemalenograstim alfa-vuxw No edit summary current
- 07:3307:33, 17 April 2024 diff hist +51 Efbemalenograstim alfa-vuxw No edit summary
- 07:3207:32, 17 April 2024 diff hist +20,075 N Efbemalenograstim alfa-vuxw Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle...."
16 April 2024
- 05:5005:50, 16 April 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 05:5005:50, 16 April 2024 diff hist +34,175 N Capivasertib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based..." current
- 05:2805:28, 16 April 2024 diff hist +15 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 05:2705:27, 16 April 2024 diff hist +33,311 N Iptacopan Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me..." current
15 April 2024
- 07:2507:25, 15 April 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:2407:24, 15 April 2024 diff hist +17,228 N Vutrisiran Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj..." current
24 March 2024
18 February 2024
- 03:1503:15, 18 February 2024 diff hist −58 User:Edzelco No edit summary
16 February 2024
- 19:0419:04, 16 February 2024 diff hist +297 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 19:0319:03, 16 February 2024 diff hist −303 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 19:0219:02, 16 February 2024 diff hist +292 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 19:0219:02, 16 February 2024 diff hist −180 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
11 February 2024
- 22:2422:24, 11 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 22:2322:23, 11 February 2024 diff hist +1,081 N Mavacamten Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART..." current
- 00:4200:42, 11 February 2024 diff hist −258 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 00:4000:40, 11 February 2024 diff hist +396 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 00:3900:39, 11 February 2024 diff hist −207 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)